Amneal Pharmaceuticals, Inc. Stock

Equities

AMRX

US03168L1052

Pharmaceuticals

Market Closed - Nasdaq 04:00:00 2024-07-02 pm EDT 5-day change 1st Jan Change
6.54 USD +1.87% Intraday chart for Amneal Pharmaceuticals, Inc. +0.62% +7.74%
Sales 2024 * 2.67B Sales 2025 * 2.79B Capitalization 1.98B
Net income 2024 * -84M Net income 2025 * 23M EV / Sales 2024 * 1.62 x
Net Debt 2024 * 2.35B Net Debt 2025 * 2.12B EV / Sales 2025 * 1.47 x
P/E ratio 2024 *
-24.2 x
P/E ratio 2025 *
93.4 x
Employees 7,850
Yield 2024 *
0.46%
Yield 2025 *
-
Free-Float 26.13%
More Fundamentals * Assessed data
Dynamic Chart
Amneal Pharmaceuticals to Develop Omalizumab Biosimilar for Allergy Treatments MT
Kashiv Biosciences Enters into Exclusive Licensing Agreement with Amneal Pharmaceuticals, Inc. for Commercialization of A Proposed Biosimilar to XOLAIR® CI
Transcript : Amneal Pharmaceuticals, Inc. Presents at Jefferies 2024 Global Healthcare Conference, Jun-05-2024 01:30 PM
Amneal Pharmaceuticals, Inc. Expands Broad Injectables Portfolio to over 40 Products with the Addition of Six New Therapies CI
Amneal Pharmaceuticals Begins Supplying Generic Version of Narcan DJ
Amneal Begins Supplying Over-The-Counter Naloxone Hydrochloride Nasal Spray to U.S. Retail Pharmacies and the State of California CI
Goldman Sachs Adjusts Amneal Pharmaceuticals Price Target to $8 From $6.25, Maintains Buy Rating MT
Truist Securities Raises Amneal Pharmaceuticals' Price Target to $9 From $7, Maintains Buy Rating MT
Drugmaker Amneal agrees to $270 million U.S. opioid settlement RE
Sector Update: Health Care Stocks Mixed Pre-Bell Friday MT
Transcript : Amneal Pharmaceuticals, Inc., Q1 2024 Earnings Call, May 03, 2024
Amneal Pharmaceuticals Q1 Adjusted Earnings, Revenue Climb MT
(AMRX) AMNEAL PHARMACEUTICALS Forecasts Fiscal Year 2024 EPS Range $0.53 - $0.63 MT
Earnings Flash (AMRX) AMNEAL PHARMACEUTICALS Reports Q1 Revenue $659.2M, vs. Street Est of $619M MT
Earnings Flash (AMRX) AMNEAL PHARMACEUTICALS Posts Q1 EPS $0.14, vs. Street Est of $0.09 MT
More news
1 day+1.87%
1 week-0.15%
Current month+2.99%
1 month-2.10%
3 months+8.10%
6 months+7.74%
Current year+7.74%
More quotes
1 week
6.29
Extreme 6.29
6.56
1 month
6.29
Extreme 6.29
7.25
Current year
5.01
Extreme 5.01
7.25
1 year
2.29
Extreme 2.29
7.25
3 years
1.24
Extreme 1.24
7.25
5 years
1.24
Extreme 1.24
7.45
10 years
1.24
Extreme 1.24
24.48
More quotes
Managers TitleAgeSince
Founder 57 01-12-31
Founder 53 01-12-31
Director of Finance/CFO 57 Nov. 06
Members of the board TitleAgeSince
Director/Board Member 66 Nov. 06
Director/Board Member 69 Nov. 06
Chairman 71 Nov. 06
More insiders
Date Price Change Volume
24-07-02 6.54 +1.87% 974,297
24-07-01 6.42 +1.10% 911,778
24-06-28 6.35 -1.09% 9,101,889
24-06-27 6.42 -0.77% 962,859
24-06-26 6.47 -0.46% 1,438,932

Delayed Quote Nasdaq, July 02, 2024 at 04:00 pm EDT

More quotes
Amneal Pharmaceuticals, Inc., is a fully integrated global essential medicine company. The Company is engaged in the development, manufacturing, and distribution of a diverse portfolio of approximately 270 pharmaceutical products, primarily within the United States. The Company’s Generics segment develops, manufactures and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products and transdermal across a broad range of therapeutic categories. The Company's Specialty segment’s portfolio includes central nervous system disorders (Parkinson’s disease, spasticity, migraine), endocrinology (hypothyroidism), and other therapeutic areas. The Company’s AvKARE segment provides pharmaceuticals, medical and surgical products, and services to government, retail, and institutional markets.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
5
Last Close Price
6.54 USD
Average target price
8.25 USD
Spread / Average Target
+26.15%
Consensus